Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 8/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.45 |
| ▸ | HPGD | P15428 | 5/20 | 0.45 |
| ▸ | MAPT | P10636 | 5/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | LNPEP | Q9UIQ6 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL872772 | 0.84 | BRD4 (0.49) | ALDH1A1HPGDMAPTLMNAPLA2G1B | |
| SCHEMBL872773 | 0.84 | BRD4 (0.49) | ALDH1A1HPGDMAPTLMNAPLA2G1B | |
| SCHEMBL18591884 | 0.84 | ALDH1A1 (0.44) | ALDH1A1HPGDMAPTLMNAPLA2G1B | |
| SCHEMBL31498654 | 0.77 | MAPT (0.40) | ALDH1A1HPGDMAPTLMNAPLA2G1B | |
| SCHEMBL30411459 | 0.74 | ALDH1A1 (0.53) | ALDH1A1HPGDMAPTLMNAPLA2G1B | |
| SCHEMBL30869908 | 0.74 | BRD4 (0.38) | ALDH1A1HPGDMAPTLMNAPLA2G1B | |
| SCHEMBL18551707 | 0.73 | ALDH1A1 (0.66) | ALDH1A1MAPTLMNAHTTSMN1; SMN2 | |
| SCHEMBL20369610 | 0.71 | ALDH1A1 (0.56) | ALDH1A1HPGDMAPTLMNAPLA2G1B | |
| SCHEMBL18551518 | 0.71 | ALDH1A1 (0.52) | ALDH1A1HPGDMAPTLMNAPLA2G1B | |
| SCHEMBL29424177 | 0.71 | MAPT (0.39) | ALDH1A1HPGDMAPTLMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230263893-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | ARVINAS OPERATIONS, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20170065719-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | ARVINAS OPERATIONS, INC. | 2017-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230263893-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | BRPF3, STUB1, BRDT | LTA4H 2645/4885ALDH1A1 3365/4885HPGD 2457/4885 |
| US-20170065719-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | BRPF3, STUB1, BRDT | LTA4H 2645/4885ALDH1A1 3365/4885HPGD 2457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.